Yildirim Huseyin, Ucgun Irfan, Yalcin Ahmet Ugur, Gulbaş Zafer, Sahin Garip, Acikalin Mustafa Fuat, Metintas Muzaffer, Ak Guntulu
Department of Chest Disease, Osmangazi University, Medical Faculty, 26480 Meselik, Eskisehir, Turkey.
Respirology. 2006 Sep;11(5):652-4. doi: 10.1111/j.1440-1843.2006.00906.x.
Diffuse alveolar haemorrhage is a severe clinical disorder that may be life-threatening. The early diagnosis of diffuse alveolar haemorrhage and prompt intervention is crucial. Recombinant factor VIIa has been used extensively for the treatment of haemophilia A and B patients. More recently, recombinant factor VIIa has been used successfully for the treatment of bleeding in patients without pre-existing coagulopathy. We describe the successful use of recombinant factor VIIa in a patient with diffuse alveolar haemorrhage secondary to pulmonary-renal syndrome.
弥漫性肺泡出血是一种可能危及生命的严重临床病症。早期诊断弥漫性肺泡出血并及时干预至关重要。重组凝血因子VIIa已广泛用于治疗甲型和乙型血友病患者。最近，重组凝血因子VIIa已成功用于治疗无既往凝血障碍患者的出血。我们描述了重组凝血因子VIIa在一名继发于肺肾综合征的弥漫性肺泡出血患者中的成功应用。
